screening and early treatment programmes. The effectiveness of such programmes has been shown in various countries such as Iceland, where CC mortality has been practically eradicated 3 and Canada, where mortality has fallen from 11.5 to 4.8 per 100 000 women. 4 According to different studies in Latin America, between 20% and 60% of all deaths attributed to CC can be avoided by means of screening programmes. 5 Exfoliative cytology (PAP) was introduced by Papanicolaou in 1941. 6 In Mexico City, the use of the PAP test began in 1949 at the Women's Hospital. 7 ' 8 In the 1960s, CC screening was carried out through two employment related health care systems: the Mexican Social Security Institute (IMSS) 9 and the Public Employees' Social Security and Services Institute (ISSSTE).
10 These large health maintenance organizations cover dose to 60% of the Mexican population. However, in spite of the long-term existence of the CC screening programme in Mexico, the number of deaths due to CC reported between 1980 and 1995 was estimated at 62 000. 2 In this paper, we present an evaluation of the screening programme currently operating in Mexico City.
The screening programme in Mexico
The Health Ministry regulates cancer detection activities by proposing the guidelines for a national programme. The PAP test is offered to women who belong and who do not belong to the social security system. Each medical institution carries out detection activities with the available infrastructure and human resources, in each of the 32 states of the Mexican Republic. In 1996 there were 463 cytotechnologjsts, 251 reading centres, 70 dysplasia clinics, and 540 gynaecological oncology units.
The national programme for early cancer detection has existed since 1974. The CCSP in Mexico only has infrastructure and resources for carrying out 3 516 000 PAP tests for an estimated population in 1996 of 16 507 011 women between 25 and 65 years of age; the official Mexican norm (until 1996) for this programme recommends annual PAP tests for women after they have begun sexual relations and does not suggest an upper age limit. A further limitation of the programme is that the official diagnostic nomenclature used in gynaecological cytology is based on dysplasias (WHO nomenclature), while other health institutions continue to use the Papanicolaou nomenclature and also the Mexican screening programme lacks epidemiological surveillance mechanisms that could guarantee follow-up and treatment of abnormalities detected. 1 '
Case-control study

Cases
We conducted a case-control study to determine the preventive effect of the CC screening programme among women in Mexico City between September 1990 and December 1992. Newly incident cases of CC were identified among women younger than 75 years of age who had been residents of the metropolitan area of Mexico City for at least 2 years. Cases were identifled from six hospitals belonging to the two major health providers in Mexico City: the Social Security system (the Gynaeco-obstetrics Hospitals 3 and 4 of the Mexican Institute for Social Security, the '20 de noviembre' Hospital of the public employee social security system and the Central Military Hospital), which provides health care to the formally employed and their families, and the Ministry of Health hospitals (General Hospital and Women's Hospital), which provide health care to the population not included in the formal sector and the unemployed. Cases were selected from women attending the gynaecological clinic of the hospital for histological confirmation following cytological diagnosis of cervical neoplasm. A total of 750 women agreed to participate and completed an interview. All women for whom the biopsy confirmed the diagnosis of CC were included as cases in the study (N = 630). The participation rate among the cases was 95%. Sixteen per cent (N = 120) of the women interviewed as potential cases were diagnosed as not having CC.
Controls
Controls were an age-stratified random sample of residents of the Mexico City metropolitan area, identified from 3694 households randomly selected from the National Household Sampling Frame. 12 The selected households were visited by interviewers, who obtained a listing of women living there. Women aged 25-80 years who had been residents of the Mexico City area for at least 2 years were considered eligible controls. The number of controls selected for each age group was established a priori to match the age distribution of cancer cases reported to the Mexico City Cancer Registry in the year before the study.
Of the households visited, there was no eligible control in 28.4%, and the eligible control refused to be interviewed in 14.6%. Only one eligible control per household was included in the study. Controls were interviewed in their homes.
Interviewers administered a questionnaire that asked about sociodemographic variables, potential risk factors for CC (induding lifestyle habits), also included was a food frequency questionnaire, reproductive and gynaecological history; including history of cervical cytology regarding: a) knowledge and perception of the usefulness of the PAP test; b) the dates of samples taken and their periodicity; c) reason for having the PAP test and, d) whether they received the results.
To evaluate the preventive role of a history of PAP tests in the development of cancer in situ and invasive CC, it is important to define the relevant period for which the smear can be considered as an action of the screening programme as opposed to a diagnostic procedure in the course of medical attention. For the purposes of this study only those smears taken at least 12 months before diagnosis in cases and 12 months before the interview in controls were considered part of the screening programme. The principal consideration for this decision was the fact that it is likely that a smear done less than 12 months before diagnosis would be due to the diagnostic process. The same definition was applied to the control group in order to maintain comparability.
In previous studies in Mexico 13 we have documented that a large proportion of women seek the PAP smear because they experience gynaecological symptoms as opposed to using the screening programme as a routine, preventive health action. We have also documented that this group has high risk of CC. In order to differentiate women who used the screening programme because they had gynaecological symptoms from those who sought screening spontaneously, we performed a separate analysis for women who sought a PAP smear due to symptoms suggestive of CC. Ignoring this in the analysis would have lead to bias, as has been suggested by other authors.
14
Statistical analysis
The statistical analysis was performed using SAS 15 and EGRET software. 16 Univariate statistics were calculated for all variables. Variables measured on a continuous scale were explored in terms of their original distribution as well as in categories. Analyses were performed for all women and for invasive and in situ CC women separately. Information on histological type of cancer was obtained by diagnosis of pathology.
The effect of PAP test history on the risk of CC was studied, examining history of PAP test, PAP without gynaecological symptoms, and PAP without gynaecological symptoms and who received PAP results. Also, the effect of the frequency of PAP test was studied.
An index of socioeconomic status was developed as suggested by Bronfman et al} 1 by combining five variables (number of people living in the house, number of rooms in the house (excluding kitchen and bathroom), availability of drinking water, sanitary conditions, and education of the head of the family).
Odds ratios and 95% confidence intervals were obtained from logistic regression models to evaluate the association between 
Results
The study included 233 cases of cancer in situ, 397 cases of invasive CC and 1005 controls from whom we obtained a full interview. Mean age was 48 (standard deviation [SD] = 13.5) for controls, 47.7 (SD = 13.1) for invasive CC cases and 44.7 (SD = 12.6) for in situ cases. The main risk faaors for cervical neoplasm among these women are described in Table 1 . The most significant factors of cancer in situ and invasive CC were; socioeconomic level, age at first birth and number of sexual partners.
In relation to the use of the screening programme we observed that controls used the programme at an earlier age (mean 35 years versus 37.2 years) and had on average a higher number of PAP smears (mean 5.1 versus 4), as compared to CC cases. When we examined the differences between invasive and in situ cases, we observed the following. The mean age when the first gynaecological cytology was performed is significantly lower in controls (mean = 35; SD = 11.8) than in invasive CC cases (mean = 37.2; SD = 14.7). However, no significant differences were observed between in situ cases (mean = 34.9; SD = 12.7) and controls. The average number of cytologies during the woman's lifetime is similar in controls (mean = 5.0; SD = 5.5) and women with cancer in situ (mean = 4.9; SD = 4.3), while invasive CC cases had a lower average as compared to controls, which in addition was statistically significant (mean = 4.3; SD = 4.6).
In relation to effect of the early detection programme, for the in situ cancer cases, we have not observed a protective effect. This result is to be expected (OR = 1.5, 95% CI : 1.14-2.10). However, when we excluded women who seek the PAP test in response to symptoms, we observed a slight decrease in the risk of invasive CC (Table 2) .
For the invasive CC cases, we observed a small, significant protective effect of the PAP smear (OR = 0.76, 95% CI : 0.59-0.98). However, once again when we excluded those cases who sought the PAP test because of symptoms (58%), the observed protective effect was stronger. When we compared women with no previous PAP with those who sought the PAP test spontaneously, we observed an OR of 0.38, 95% CI : 0.28-0.52 (Table 2) .
When we looked at greater or lesser frequency of PAP tests as a risk factor for CC, we observed an increasing risk with increasing time span between tests (Table 3) . For in situ cases, the OR for CC increased from 1.34 to 2.23 when we compared time spans between PAP tests of 3-4 years and more than 9 years. Similar trends were observed for invasive cases. This protective effect became more apparent when we included women who sought the test spontaneously (Table 3) .
We observed that, of the total sample 40% of CC cases were avoided among women with complete PAP tests (CI: 30-54%), and 11 % were avoided on a population level, and we estimated the preventable fraction by the method suggested by Walter. 20 The proportion of cases of CC avoided by the screening programme was 45%, assuming that all smear tests reported by participants were effective.
Discussion
The CC early detection programme in Mexico has a protective effect in relation to invasive CC, which is not observed for in situ cancer. This result is to be expected, and has been described previously, given that only those PAP tests obtained before the invasive phase of the disease can prevent invasive CC. The marginal protective effect observed for in situ cancer among women who seek testing without gynaecological symptoms and who did receive the results of their PAP test, is probably because women are encouraged to have the PAP test yearly in Mexico. Case-control studies are not appropriate for the study of the risk of precursor lesions (cervical intra-epithelial neoplasm). These lesions can only be diagnosed by screening, and a case series assembled from a screening clinic will represent prevalent cases of disease.
Likewise, we observed in Mexico City a greater protective effect in women who sought screening spontaneously, without gynaecological symptoms. We also observed a protective effect among regular users of the PAP test; the highest risk of CC was observed when PAP tests are performed more than 9 years apart.
Several limitations need to be considered in our study. In case-control designs, results are susceptible to bias because of differences in the accuracy of information provided by cases and controls. Bias could also occur because having CC could affect the variables under study or bias could result from case and control selection.
In this study cases were interviewed in hospitals, and were therefore more willing to participate than controls. Also, cases probably knew about their CC diagnosis at the moment of the interview. These differences may have affected the comparability of the interviews. If this were true, we could assume that cases would give more detailed and accurate information about their PAP test histories, which would lead to a greater number of cases with a history of PAP tests than controls. This would Odds raao adjusted for age, age at start of sex life, number of normal births, number of sex partners and sodoeconomic level. lead to underestimation of the effect, suggesting that the real effect may be larger than the one we observed. It is particularly important in this study to avoid the bias resulting from the CC diagnosis. When a woman's history of PAP testing is analysed without taking into account the presence of symptoms as a determinant of seeking a PAP smear, no protective effect related to the programme is observed. To avoid this bias the analysis only included those PAP tests done at least 1 year before the date of diagnosis or the interview, tests not done because of the presence of gynaecological symptoms and test results which were delivered to the patient within a reasonable time. This stratification was observed to be the most appropriate, since the relation between having gynaecological symptoms and having invasive uterine CC was very important (OR = 27.2, 95% CI: 16.6-44.5), indicating that the presence of gynaecological symptoms is a strong predictor of cervical cancer.
All cases in our study had diagnostic cytological certification and histological confirmation. Half (50.7%) of the controls received a PAP test and only two cases of cancer were detected among them, suggesting that bias from misdassification of disease is unimportant. The fact that known risk factors, such as higher numbers of sex partners and births, were also found among controls supports the validity of the methods and results of our study. Table 4 summarizes data from studies that have used epidemiological design to evaluate CC screening programmes.
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All of the studies have presented evidence that the programmes provide protection and that a history of PAP tests is more common in healthy women than among those diagnosed with CC. Only two of the studies published were done in Latin American countries and both show that screening programmes provide protection. 27 ' 34 The study by Herrero era/. 34 included a sample of Mexican women. Unfortunately, the data are not broken down by country, which would have allowed for comparison with our study. These authors compared a history of PAP testing in 759 cases and 1430 controls (including hospital and population controls from various countries) and reported a reduction in risk of 2.5 times, a figure very close to that observed in our study for the invasive CC cases. This study found that 50% of cases had never had a PAP test, compared to 25% of controls. These percentages for PAP test history are also similar to those found in our study (50.7 in controls, 60.8% in cancer in situ and 42.4% in invasive CC). This is assuming that all PAP tests reported by participants were effective, meaning that they were not done in response to symptoms suggesting cancer, that results were delivered in reasonable time and that therapeutic action was correct. This proportion should be reflected in mortality rates and should have led to decreasing mortality over time. However, because the assumptions mentioned above are often actually not true, this figure probably overestimates the protective effect of the screening programme.
The results of this research show a protective effect for invasive CC attributable to the screening programme. However, this effect is small when examined from a population perspective. This could be because coverage (the proportion of women with complete tests) of the population is relatively low; only 50.7% of the women interviewed said they had ever had a test. Another reason for the programme's limited effect is the high percentage of women who seek a PAP test because they have symptoms. In our study we found that of the total sample, 55% of cases were screened because of CC related symptoms. The information presented in this study suggests the need to guarantee the quality of the early cancer detection programme, and also of investigation into new alternatives for prevention, diagnosis and treatment in Mexico and in many Latin American countries. One of the principal elements that should be modified is the recommendation requiring annual PAP testing for all women. This could be changed to testing every 3 years for women who have had a previous, negative smear result. This would make the expansion of the detection programme's coverage more feasible. The potential benefits of such expansion would be considerable because in Mexico every 2 hours there is a death from CC.
The reduction in mortality would avoid the high social cost associated with this disease and would also lead to savings in the material and human resources needed for the treatment of CC when it is diagnosed at an advanced stage.
In countries with high CC mortality rates, operational research must be done into screening activities in order to generate the information necessary for implementing changes in the population's attitudes and practices with regard to screening. Such research could also be used to prompt decision-makers to improve the quality and availability of screening currently provided by health services.
